Spots Global Cancer Trial Database for myelodysplasia
Every month we try and update this database with for myelodysplasia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer | NCT00312429 | Hematologic Neo... | Stem Cell Trans... | 18 Years - 70 Years | Duke University | |
| Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | NCT00795132 | Acute Leukaemia Chronic Disease Leukemia Myelodysplasia Lymphoma | Busulfan Anti-Thymocyte ... Fludarabine Cyclosporine Mycophenolate m... | - 21 Years | University of Utah | |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | NCT00136422 | Acute Myelogeno... Myelodysplasia | autologous tumo... | 18 Years - | Dana-Farber Cancer Institute | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis | NCT04800458 | Thrombocytopeni... Immune Thromboc... Myelodysplasia | Blood samples | 18 Years - | University Hospital, Bordeaux | |
| The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes | NCT00247026 | Myelodysplastic... | curcumin; coenz... | 16 Years - | Hadassah Medical Organization | |
| Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | NCT00195533 | Hematological M... Leukemia Myelodysplasia Lymphoma Myeloma Stem Cell Trans... | piperacillin-ta... glycopeptide | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. | NCT01933035 | Immune Thromboc... Chemotherapy In... Myelodysplasia Aplastic Anaemi... | Immune Thromboc... Hypo-proliferat... Control Populat... | 18 Years - | Beth Israel Medical Center | |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | NCT00597714 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | Non-myeloablati... | 18 Years - | Duke University | |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | NCT00514722 | Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Multiple Myelom... Lymphoma, Large... Lymphoma, Mantl... Lymphoma, T-Cel... T-NK Cell Lymph... Hodgkin Disease | umbilical cord ... | 18 Years - 55 Years | University of California, San Francisco | |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | NCT01904175 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | 18 Years - | Duke University | ||
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | NCT06303193 | Myelodysplastic... | pacritinib | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | NCT00580034 | Lymphoma Myeloma Leukemia Myelodysplasia Solid Tumors | Campath Purged ... Donor Apheresis | 17 Years - | Duke University | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | NCT05794880 | Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant... | Magnetic-Activa... | 0 Years - 25 Years | Medical College of Wisconsin | |
| Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants | NCT00606437 | Lymphoma Myeloma Leukemia Myelodysplasia Solid Tumors Hodgkin's Disea... Myelofibrosis | Total Body Irra... | 14 Years - 65 Years | Duke University | |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | NCT00109538 | Myelodysplastic... Leukemia, Myelo... Myelodysplasia Myelomonocytic | Lonafarnib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy | NCT05154474 | Metastatic Canc... Cancer, Breast Cancer Colon Cancer, Rectum Cancer, Lung Cancer Ovaries Cancer Prostate Cancer, Kidney Cancer Pancreas Myeloma Myelodysplasia Leukemia, Myelo... Leukemia,Myeloi... Leukemia, Lymph... Leukemia, Lymph... | Standard | 18 Years - | Weprom | |
| StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | NCT02765997 | Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Myelodysplasia | Unmanipulated U... SR-1 UCB | 2 Years - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | NCT00136422 | Acute Myelogeno... Myelodysplasia | autologous tumo... | 18 Years - | Dana-Farber Cancer Institute | |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | NCT00975975 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Myelofibrosis Anemia, Aplasti... Hemoglobinuria,... | Basiliximab | 18 Years - | Indiana University | |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | NCT00109538 | Myelodysplastic... Leukemia, Myelo... Myelodysplasia Myelomonocytic | Lonafarnib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | NCT00195533 | Hematological M... Leukemia Myelodysplasia Lymphoma Myeloma Stem Cell Trans... | piperacillin-ta... glycopeptide | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Decitabine, Cytarabine, GCSF for Refractory AML/MDS | NCT00740181 | Myelodysplasia Leukemia | chemotherapy | 19 Years - | Brown University | |
| Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia | NCT00677859 | Hematologic Mal... | MultiStem® MultiStem® | 18 Years - 65 Years | Healios K.K. | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Tissue Microarray of Hematological Malignancies | NCT04142372 | Hematological M... | - | Tampere University Hospital | ||
| Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant | NCT00354120 | Acute Myeloblas... Lymphoblastic L... Myelodysplasia Chronic Myeloid... Myelofibrosis Lympho-prolifer... | Alentuzumab Globulina antil... | 18 Years - 65 Years | Gruppo Italiano Trapianto di Midollo Osseo | |
| Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy | NCT01956799 | Myelodysplasia Myelofibrosis Aplastic Anemia | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | ||
| Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS | NCT04166929 | Acute Myeloid L... Myelodysplasia | Haplo SCT with ... Haplo SCT | 18 Years - 75 Years | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) | NCT05260203 | Multiple Myelom... Solitary Plasma... Amyloidosis Chronic Myeloid... Chronic Lymphoc... T Cell Non-Hodg... Lymphocytic Lym... Hodgkin Lymphom... B-cell Non Hodg... Acute Myeloid L... Myelodysplasia Chronic Myelopr... Treatment Adher... Treatment Adher... | RITA (App) | 18 Years - | Advice Pharma Group srl | |
| Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS | NCT04166929 | Acute Myeloid L... Myelodysplasia | Haplo SCT with ... Haplo SCT | 18 Years - 75 Years | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | NCT01297543 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Myelodysplasia | human myeloid p... G-CSF | 18 Years - | Cellerant Therapeutics | |
| Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | NCT00580034 | Lymphoma Myeloma Leukemia Myelodysplasia Solid Tumors | Campath Purged ... Donor Apheresis | 17 Years - | Duke University | |
| Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | NCT01422603 | Acute Myeloid L... Myelodysplasia | Clofarabine Clofarabine | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. | NCT01718379 | Myelodysplastic... | Lenalidomide Epoetin beta | 18 Years - | Groupe Francophone des Myelodysplasies | |
| Decitabine, Cytarabine, GCSF for Refractory AML/MDS | NCT00740181 | Myelodysplasia Leukemia | chemotherapy | 19 Years - | Brown University | |
| Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | NCT00516152 | Chronic Myeloid... Acute Myelogeno... Myelodysplasia Acute Lymphocyt... Severe Aplastic... Non-Hodgkin's L... Lymphoprolifera... Multiple Myelom... Advanced Myelop... | Busulfan/Fludar... | 15 Years - 61 Years | University of California, San Francisco | |
| MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | NCT05794880 | Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant... | Magnetic-Activa... | 0 Years - 25 Years | Medical College of Wisconsin | |
| Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis | NCT04800458 | Thrombocytopeni... Immune Thromboc... Myelodysplasia | Blood samples | 18 Years - | University Hospital, Bordeaux | |
| Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | NCT01422603 | Acute Myeloid L... Myelodysplasia | Clofarabine Clofarabine | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | NCT03480360 | Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Myelodysplasia Myeloproliferat... Myelofibrosis Lymphoma Lymphoma, Non-H... Plasma Cell Dis... | Cyclophosphamid... Fludarabine Total Body Irra... Tacrolimus cellcept g-csf Peripheral Bloo... | 18 Years - 75 Years | Dartmouth-Hitchcock Medical Center | |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | NCT01904175 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | 18 Years - | Duke University | ||
| Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations | NCT01911871 | Thalassemia Sickle Cell Dis... Myelodysplasia | Blood sample | 6 Years - | Assistance Publique - Hôpitaux de Paris | |
| ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | NCT01110473 | Acute Lymphobla... Acute Myelogeno... B-cell Chronic ... Chronic Myeloge... Myelodysplasia | ABT-348 ABT-348 ABT-348 and aza... ABT-348 | 18 Years - 99 Years | AbbVie | |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | NCT03682536 | Myelodysplastic... | Luspatercept Epoetin alfa | 18 Years - | Celgene | |
| Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies | NCT02323867 | Leukemia Lymphoma Myelodysplasia | Alpha Beta T ce... | - 23 Years | Children's Hospital of Philadelphia | |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | NCT00975975 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Non-Hodgkin's L... Hodgkin's Disea... Multiple Myelom... Myelofibrosis Anemia, Aplasti... Hemoglobinuria,... | Basiliximab | 18 Years - | Indiana University | |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | NCT00597714 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | Non-myeloablati... | 18 Years - | Duke University | |
| Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents | NCT03387475 | Myelodysplasia | Deferasirox | 18 Years - 100 Years | University Hospital, Grenoble | |
| Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | NCT00513175 | Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Lymphoc... Follicular Lymp... Multiple Myelom... NHL Myeloproliferat... Chronic Myeloid... Renal Cell Carc... Aplastic Anemia | 16 Years - 75 Years | University of California, San Francisco | ||
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | NCT01904175 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | 18 Years - | Duke University | ||
| Sitagliptin Umbilical Cord Blood Transplant Study | NCT00862719 | Leukemia, Myelo... Acute Lymphobla... Myelodysplasia Leukemia, Myelo... Lymphoma, Non-H... | Sitagliptin | 18 Years - 59 Years | Indiana University | |
| HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | NCT00145626 | Acute Myeloid L... Acute Lymphocyt... Myelodysplasia Chronic Myeloid... Histiocytosis | Chemotherapy an... Miltenyi Biotec... Allogeneic stem... | - 24 Months | St. Jude Children's Research Hospital | |
| MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | NCT05794880 | Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant... | Magnetic-Activa... | 0 Years - 25 Years | Medical College of Wisconsin | |
| Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia | NCT00677859 | Hematologic Mal... | MultiStem® MultiStem® | 18 Years - 65 Years | Healios K.K. | |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | NCT00109538 | Myelodysplastic... Leukemia, Myelo... Myelodysplasia Myelomonocytic | Lonafarnib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes | NCT00899223 | Acute Leukemia Chronic Leukemi... Myelodysplasia | biologic sample... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia | NCT00580242 | Myelodysplasia | Bortezomib Bortezomib Bortezomib Lenalidomide | 18 Years - | Massachusetts General Hospital | |
| Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders | NCT00511537 | CML ALL AML Myelodysplasia Lymphoma Myeloproliferat... | 16 Years - 54 Years | University of California, San Francisco | ||
| Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS | NCT04166929 | Acute Myeloid L... Myelodysplasia | Haplo SCT with ... Haplo SCT | 18 Years - 75 Years | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | NCT00393380 | Leukemia, Myelo... Anemia, Aplasti... Myelofibrosis Lymphoma Hodgkin Disease Leukemia, Lymph... Leukemia, Myelo... Leukemia, Lymph... | Parathyroid Hor... | 18 Years - 45 Years | The Emmes Company, LLC | |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia | NCT00776503 | Myelodysplastic... | VORINOSTAT | 18 Years - | Groupe Francophone des Myelodysplasies | |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | NCT01500161 | Acute Myelogeno... Acute Lymphocyt... Chronic Lymphoc... Chronic Myeloge... Hodgkins Diseas... Non-Hodgkins Ly... Aplastic Anemia Multiple Myelom... Myelodysplastic... | Busulfan Clofarabine Fludarabine Melphalan Carmustine Etoposide Cytarabine | 18 Years - 65 Years | Texas Oncology Cancer Center | |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | NCT03682536 | Myelodysplastic... | Luspatercept Epoetin alfa | 18 Years - | Celgene | |
| Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies | NCT02323867 | Leukemia Lymphoma Myelodysplasia | Alpha Beta T ce... | - 23 Years | Children's Hospital of Philadelphia | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | NCT01297543 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Myelodysplasia | human myeloid p... G-CSF | 18 Years - | Cellerant Therapeutics | |
| Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer | NCT00312429 | Hematologic Neo... | Stem Cell Trans... | 18 Years - 70 Years | Duke University | |
| In-Vivo Activated T-Cell Depletion to Prevent GVHD | NCT00594308 | Acute Myelogeno... Acute Lymphocyt... Chronic Myeloge... Chronic Lymphoc... Myelodysplasia Lymphoma, Non-H... Mantle-Cell Lym... Hodgkin's Disea... Multiple Myelom... Myelofibrosis | Cyclophosphamid... Fludarabine Cyclosporine Mycophenolate m... Basiliximab | 18 Years - 75 Years | Indiana University | |
| Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot | NCT01615146 | Myelodysplastic... Leukemia | Platelet Transf... | 18 Years - | Ottawa Hospital Research Institute | |
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | NCT00136422 | Acute Myelogeno... Myelodysplasia | autologous tumo... | 18 Years - | Dana-Farber Cancer Institute | |
| Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia | NCT02007863 | Leukemia Myelodysplasia Acute Lymphocyt... Acute Myelogeno... | Umbilical Cord ... Fludarabine Busulfan Melphalan | - 21 Years | University of Miami | |
| ATG Plus PTCy vs ATG for CGVHD Prophylaxis | NCT04202835 | Acute Leukemia Myelodysplasia Chronic Graft-v... | Cyclophosphamid... Anti-Thymocyte ... | 16 Years - 70 Years | McMaster University | |
| Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome. | NCT01868477 | Low and Int 1-r... | Deferasirox DFX... Erythropoietin ... Deferasirox DFX... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
